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The object of this work was to test the hypothesis that failure to secrete the Z variant of human a,-antitryp- 
sin is related to the loss of a particular structural feature, the Lys-290 to Glu-342 salt bridge. Oligonucleo- 
tide-directed mutagenesis was used to disrupt the salt bridge by substituting a glutamic acid for lysine at 
residue 290. RNA transcripts prepared from this mutant DNA and from the normal cDNA were both able 
to direct the synthesis of protein in a cell-free system and after injection into Xenopus oocytes. Furthermore, 
the constructed mutant cr,-antitrypsin was secreted as readily as the normal inhibitor. 
cl,-Antitrypsin; Z variant; Site-directed mutagenesis; q-Antitrypsin secretion; (Xenopus oocyte) 
1. INTRODUCTION 
cur-Antitrypsin (AAT) is the principal protease 
inhibitor found in human serum. The main func- 
tion of the protein appears to be the inhibition of 
neutrophil elastase and thereby the prevention of 
proteolytic damage to the lung [l-3]. The natural- 
ly occurring Z variant of the inhibitor is syn- 
thesised in hepatocytes but its secretion from these 
cells is inefficient compared to that of the normal, 
M variant [4,5]. A point mutation changes 
glutamic acid at residue 342 in the normal protein 
to lysine in the Z variant and this single substitu- 
tion is responsible for the secretory defect [6,7]. 
The failure to secrete Z ai-antitrypsin is not con- 
fined to the hepatocyte. Xenopus oocytes injected 
with liver mRNAs from normal and PiZZ in- 
dividuals synthesise cur-antitrypsin but the Z pro- 
tein accumulates intracellularly while the M 
variant is readily secreted [8,9]. How a single 
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amino acid substitution produces such a radical 
change in protein transport is still far from clear 
however, crystallographic studies [lo] have sug- 
gested that Glu-342 forms a salt bridge with 
Lys-290 in the normal inhibitor. The loss of this 
feature in the Z variant is thought to have an effect 
on the folding of the newly synthesised protein and 
prevent its subsequent passage along the secretory 
pathway. To study this possibility I have used site- 
directed mutagenesis to disrupt the salt bridge 
from ‘the other side’ by replacing the lysine at 290 
with glutamic acid. Messenger RNAs coding for 
normal and Lys-290-Glu mutant AATs were in- 
jected into Xenopus oocytes to measure the effect 
of this mutation on the secretion of the inhibitor. 
2. MATERIALS AND METHODS 
All DNA and RNA modifying enzymes were 
from BRL (Bethesda Research Laboratories) or 
New England Biolabs. The oligonucleotide adap- 
tor was from Pharmacia. Radiolabelled com- 
pounds and the reticulocyte lysate translation kit 
were from Amersham. M 13 vectors and bacterial 
strains for site-directed mutagenesis were from 
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Anglian Biotechnology. Other reagents were 
Analar grade or better and were supplied by 
Sigma. General methods and the use of restriction 
enzymes have been described elsewhere [l I]. 
Oligonucleotides for mutagenesis and sequenc- 
ing were prepared on a Pharmacia gene assembler 
and purified by polyacrylamide gel electrophoresis 
and UV shadowing or by HPLC on a Whatman 
Particel 10 SAS column. Oligonucleotide-directed 
mutagenesis was undertaken essentially as de- 
scribed [ 12,131. Putative mutants were sequenced 
using the dideoxynucleotide chain termination 
method [ 141. 
The vector SP64T [‘15] was cut with Bg/II at a 
site between the 5 ‘- and 3’-flanking regions and a 
PstI adaptor inserted at this point. The PstI site in 
the polylinker was removed before ligation of the 
AAT sequences into the vector. Constructs were 
linearised by cleavage with XbaI and transcribed 
with SP6 polymerase according to the manufac- 
turer’s instructions except for the addition of 
0.5 mM m7G(5’)ppp(5’)G to the reaction mix 
[161. 
The preparation and micro-injection of 
Xenopus oocytes was as described by Colman [ 171, 
Oocytes were.injected with -20 ng of RNA or an 
equal volume of sterile water then cultured in 
unlabelled Barth’s saline for 18 h. Unhealthy 
oocytes were discarded and the remaining oocytes 
cultured in Barth’s saline containing 0.8 mCi * ml-’ 
[3’S]methionine for 24 h. Oocyte extracts and in- 
cubation media were immunoprecipitated as 
previously described [8]. 
Translation assays and immunoprecipitates were 
analysed by SDS-polyacrylamide gel elec- 
trophoresis on 10% gels followed by fluorography 
P3,181. 
3. RESULTS AND DISCUSSION 
To examine the function of the Lys-290-Glu- 
342 salt bridge the lysine residue was replaced with 
a glutamic acid to ensure the complete disruption 
of the salt bridge and to approximate the charge 
repulsion found in the Z protein. To do this a 17 
base oligonucleotide was synthesised with a single 
mismatch at the first base of the Lys-290 codon 
(AAA to GAA). A full length cDNA for ar-anti- 
trypsin [19], was cloned in an Ml3 mp8 vector and 
the desired mutant generated as described by 
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Winter et al. [ 121. The mutant gene was sequenced 
to ensure the desired mutation was in place. It was 
then excised and inserted into the ‘translation vec- 
tor’ to give the construct shown in fig.1. This vec- 
tor is a modification of that described by Krieg and 
Melton [ 151. The 5 ’ -flanking region from Xenopus 
globin mRNA contributes a capping site and 
ribosome binding site to allow the transcription of 
readily translatable AAT mRNA. To permit cor- 
rect alignment of the AAT cDNA in relation to the 
flanking sequences a PstI site has been inserted 
downstream from the 5 ‘-flanking region and a 
similar site deleted from the polylinker sequence. 
In vitro transcripts were synthesised in the presence 
of m’G(5 ‘)ppp(5 ‘) to produce capped RNAs for 
subsequent protein synthesis [ 161. 
Translation of normal and mutant coding RNAs 
in a reticulocyte lysate cell-free system labelled 
with [35S]methionine showed that both species 
directed the production of protein (fig.2). In both 
cases strong bands of equal intensity were pro- 
duced (relative molecular mass 46 kDa) which cor- 
responded in size to the translation product from 
total human liver mRNA immunoprecipitated with 
antiserum raised against plasma AAT. The 
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Fig.1. Structure of the SP6 translation vector and 
sequences of AAT and the Lys-290-Glu mutant DNAs. 
The cross-hatched zone indicates mature al-antitrypsin 
coding sequences and the inner dark region represents 
the area for site-directed mutagenesis. RNA synthesis 
starts at the SP6 promoter and proceeds clockwise. 
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Fig.2. The translation of normal and Lys-290 to Glu 
transcripts in a reticulocyte lysate cell-free translation 
system. Lanes: 1, control without added mRNA; 2, 
normal AAT RNA; 3, Lys-290 to Glu RNA. The arrow 
indicates the position of immunoprecipitated AAT from 
translation of total human liver poly(A+) RNA. 
presence of full length polypeptides after cell-free 
translation indicates the absence of incomplete 
transcripts, a point that might be obscured by the 
post-translational modifications undertaken by the 
oocyte [8,20]. 
To investigate the effect of the Lys-290 to 
glutamate mutation on the secretion of AAT, nor- 
mal and mutant RNAs were injected into oocytes 
from Xenopus laevis (fig.3). Both transcripts pro- 
Fig.3. Injection of normal and mutant coding transcripts 
into Xenopus oocytes. S, secreted material; 0, species 
from oocyte extracts. Lanes: 1, uninjected oocytes; 2, 
injection of normal AAT transcript; 3, Lys-290 to Glu 
RNA; 4, injection of normal (PiMM) human liver 
poly(A+) RNA; 5, poly(A+) RNA from a Z homozygote. 
duced an intracellular species with a molecular 
mass of 54 kDa corresponding to the partially 
glycosylated precursor and a secreted AAT with a 
molecular mass of 58 kDa, equivalent o the fully 
glycosylated protein. Secreted bands were of equal 
intensity showing that normal and mutant proteins 
were efficiently transported by the oocyte secretory 
apparatus. Translation of normal human liver 
mRNA in the same system supports the view that 
both SP6 transcripts direct the synthesis of protein 
that is exported as readily as the authentic liver 
species. This is in contrast to the aberrant secretion 
of inhibitor synthesised by liver mRNA from a pa- 
tient homozygous for the Z gene, also shown in 
fig.3. 
Crystallographic studies on the structure of 
AAT are complicated by difficulties in crystallising 
the intact protein but measurements using a pro- 
teolytically modified inhibitor have demonstrated 
the proximity of Lys-290 and Glu-342 [lo]. The 
possibility of ionic interaction is confirmed by pro- 
tein modelling using FRODO graphics (R.C.F. and 
M.J. Sternberg, unpublished). But the present 
work makes it plain that the absence of the salt 
bridge is not responsible for the failure to secrete 
the Z variant since the Lys-290~Glu mutant AAT 
described here also lacks the salt link and displays 
a charge repulsion similar to the Z protein but does 
not accumulate intracellularly. 
81 
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The disruption of this salt bridge in the Z protein 
may be of secondary importance to the local 
changes in structure around position 342 caused by 
the glutamic acid to lysine mutation. Putative se- 
quences causing the retention of a protein in the 
endoplasmic reticulum have been identified [21] 
and it may be that the Z mutation produces or un- 
masks just such an intracellular signal. Recently 
another point mutation has been identified in the 
Z type al-antitrypsin gene [22]. Although this 
mutation (Val-213 to Ala-213) is unlikely to pro- 
duce major changes in protein structure there is the 
possibility that it has a synergistic effect on the 
Glu-342 to Lys-342 mutation. This possibility is 
also open to investigation using site-directed 
mutagenesis techniques. 
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